866-997-4948(US-Canada Toll Free)

Cancer Pain - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Mar 2014

Category :

Cancer

No. of Pages : 146 Pages

Cancer Pain Pipeline Review, H1 2014, provides an overview of the Cancer Pains therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Cancer Pain
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
  • The report reviews key players involved in the therapeutics development for Cancer Pain and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Cancer Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Cancer Pain pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Cancer Pain
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content

Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Cancer Pain Overview 11
Therapeutics Development 12
Pipeline Products for Cancer Pain - Overview 12
Pipeline Products for Cancer Pain - Comparative Analysis 13
Cancer Pain - Therapeutics under Development by Companies 14
Cancer Pain - Therapeutics under Investigation by Universities/Institutes 18
Cancer Pain - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Unknown Stage Products 22
Cancer Pain - Products under Development by Companies 23
Cancer Pain - Products under Investigation by Universities/Institutes 25
Cancer Pain - Companies Involved in Therapeutics Development 26
Amgen Inc. 26
AstraZeneca PLC 27
BioDelivery Sciences International, Inc. 28
Nektar Therapeutics 29
Daiichi Sankyo Company, Limited 30
Egalet Corporation 31
Aphios Corporation 32
AcelRx Pharmaceuticals, Inc. 33
Nippon Kayaku Co., Ltd. 34
Nippon Shinyaku Co., Ltd. 35
Orion Oyj 36
Pfizer Inc. 37
Zeria Pharmaceutical Co Ltd 38
GW Pharmaceuticals plc 39
IntelGenx Corp. 40
Benitec Biopharma Limited 41
Kolon Life Science, Inc. 42
Teikoku Seiyaku Co., Ltd. 43
BioAlliance Pharma SA 44
tesa Labtec GmbH 45
Colby Pharmaceutical Company 46
Grunenthal GmbH 47
AngioChem Inc. 48
WEX Pharmaceuticals Inc. 49
Virobay Inc. 50
QRxPharma Limited 51
Winston Pharmaceuticals, Inc. 52
Encore Therapeutics Inc. 53
Afferent Pharmaceuticals, Inc. 54
Relevare Pharmaceuticals Ltd. 55
Northern Light Pharmaceuticals AB 56
Cancer Pain - Therapeutics Assessment 57
Assessment by Monotherapy Products 57
Assessment by Combination Products 58
Assessment by Target 59
Assessment by Mechanism of Action 62
Assessment by Route of Administration 65
Assessment by Molecule Type 67
Drug Profiles 69
fentanyl citrate - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
nabiximols - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Tetrodotoxin - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
cebranopadol - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
tramadol hydrochloride SR - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
TK-641 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
tapentadol hydrochloride ER - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
hydromorphone - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
tanezumab - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
saracatinib - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
(morphine + oxycodone) CR - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
ARX-02 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
morphine sulfate ER - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
fulranumab - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
sufentanil - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
dexmedetomidine hydrochloride - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
fentanyl - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
PGN-202 - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
fentanyl citrate SR - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
leconotide - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
dronabinol - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
VBY-825 - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
zucapsaicin - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
ANG-2002 - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
Z-360 - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
ddRNAi Program For Cancer-Associated Pain - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
NKTR-192 - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
buprenorphine hydrochloride ER - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
AF-353 - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
INT-0028 - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
DD-04107 - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
QX-314 - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
ifenprodil - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
Calpastatin - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
Small Molecule To Antagonize Chemokine Receptor For Cancer Pain - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
KLS-2010 - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
Ph Alpha-1-Beta - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
BBI-11008 - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
CPC-703 - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
Cancer Pain - Recent Pipeline Updates 124
Cancer Pain - Dormant Projects 138
Cancer Pain - Discontinued Products 139
Cancer Pain - Product Development Milestones 140
Featured News & Press Releases 140
Feb 18, 2014: Preclinical Data on Angiochem Pain Program Published in Journal of Clinical Investigation 140
Feb 10, 2014: Sorrento Therapeutics Expands its Exclusive Rights to Cynviloq to Include Australia, Canada and Mexico 140
Dec 05, 2013: Orion settles patent dispute over the proprietary drug Precedex 141
Jul 29, 2013: BioDelivery Sciences Announces Regulatory Approval of ONSOLIS in Taiwan 141
May 10, 2013: Durect Announces Pfizer\'s Update On Investigational Pain Drug Remoxy 142
May 09, 2013: Purdue Pharma To Present Data Regarding Long-Term Opioid Therapy At APS Annual Meeting 142
Apr 05, 2013: Phosphagenics Receives Approval To Conduct Clinical Study Of Oxycodone Patch At Royal Adelaide Hospital 143
Apr 03, 2013: GW Pharma Receives US Patent Allowance For Delivery Of Sativex Formulation 143
Feb 14, 2013: US Federal Court Validates Cephalon’s Fentora Patents 144
Oct 15, 2012: BioDelivery Sciences Announces Launch Of Breakyl In EU 144

Appendix 145
Methodology 145
Coverage 145
Secondary Research 145
Primary Research 145
Expert Panel Validation 145
Contact Us 146
Disclaimer 146

List of Table


Number of Products under Development for Cancer Pain, H1 2014 12
Number of Products under Development for Cancer Pain - Comparative Analysis, H1 2014 13
Number of Products under Development by Companies, H1 2014 15
Number of Products under Development by Companies, H1 2014 (Contd..1) 16
Number of Products under Development by Companies, H1 2014 (Contd..2) 17
Number of Products under Investigation by Universities/Institutes, H1 2014 18
Comparative Analysis by Late Stage Development, H1 2014 19
Comparative Analysis by Clinical Stage Development, H1 2014 20
Comparative Analysis by Early Stage Development, H1 2014 21
Comparative Analysis by Unknown Stage Development, H1 2014 22
Products under Development by Companies, H1 2014 23
Products under Development by Companies, H1 2014 (Contd..1) 24
Products under Investigation by Universities/Institutes, H1 2014 25
Cancer Pain - Pipeline by Amgen Inc., H1 2014 26
Cancer Pain - Pipeline by AstraZeneca PLC, H1 2014 27
Cancer Pain - Pipeline by BioDelivery Sciences International, Inc., H1 2014 28
Cancer Pain - Pipeline by Nektar Therapeutics, H1 2014 29
Cancer Pain - Pipeline by Daiichi Sankyo Company, Limited, H1 2014 30
Cancer Pain - Pipeline by Egalet Corporation, H1 2014 31
Cancer Pain - Pipeline by Aphios Corporation, H1 2014 32
Cancer Pain - Pipeline by AcelRx Pharmaceuticals, Inc., H1 2014 33
Cancer Pain - Pipeline by Nippon Kayaku Co., Ltd., H1 2014 34
Cancer Pain - Pipeline by Nippon Shinyaku Co., Ltd., H1 2014 35
Cancer Pain - Pipeline by Orion Oyj, H1 2014 36
Cancer Pain - Pipeline by Pfizer Inc., H1 2014 37
Cancer Pain - Pipeline by Zeria Pharmaceutical Co Ltd, H1 2014 38
Cancer Pain - Pipeline by GW Pharmaceuticals plc, H1 2014 39
Cancer Pain - Pipeline by IntelGenx Corp., H1 2014 40
Cancer Pain - Pipeline by Benitec Biopharma Limited, H1 2014 41
Cancer Pain - Pipeline by Kolon Life Science, Inc., H1 2014 42
Cancer Pain - Pipeline by Teikoku Seiyaku Co., Ltd., H1 2014 43
Cancer Pain - Pipeline BioAlliance Pharma SA, H1 2014 44
Cancer Pain - Pipeline by tesa Labtec GmbH, H1 2014 45
Cancer Pain - Pipeline by Colby Pharmaceutical Company, H1 2014 46
Cancer Pain - Pipeline by Grunenthal GmbH, H1 2014 47
Cancer Pain - Pipeline by AngioChem Inc., H1 2014 48
Cancer Pain - Pipeline by WEX Pharmaceuticals Inc., H1 2014 49
Cancer Pain - Pipeline by Virobay Inc., H1 2014 50
Cancer Pain - Pipeline by QRxPharma Limited, H1 2014 51
Cancer Pain - Pipeline by Winston Pharmaceuticals, Inc., H1 2014 52
Cancer Pain - Pipeline by Encore Therapeutics Inc., H1 2014 53
Cancer Pain - Pipeline by Afferent Pharmaceuticals, Inc., H1 2014 54
Cancer Pain - Pipeline by Relevare Pharmaceuticals Ltd., H1 2014 55
Cancer Pain - Pipeline by Northern Light Pharmaceuticals AB, H1 2014 56
Assessment by Monotherapy Products, H1 2014 57
Assessment by Combination Products, H1 2014 58
Number of Products by Stage and Target, H1 2014 61
Number of Products by Stage and Mechanism of Action, H1 2014 64
Number of Products by Stage and Route of Administration, H1 2014 66
Number of Products by Stage and Molecule Type, H1 2014 68
Cancer Pain Therapeutics - Recent Pipeline Updates, H1 2014 124
Cancer Pain - Dormant Projects, H1 2014 138
Cancer Pain - Discontinued Products, H1 2014 139

List of Chart


Number of Products under Development for Cancer Pain, H1 2014 12
Number of Products under Development for Cancer Pain - Comparative Analysis, H1 2014 13
Number of Products under Development by Companies, H1 2014 14
Comparative Analysis by Late Stage Development, H1 2014 19
Comparative Analysis by Clinical Stage Development, H1 2014 20
Comparative Analysis by Early Stage Products, H1 2014 21
Assessment by Monotherapy Products, H1 2014 57
Number of Products by Top 10 Target, H1 2014 59
Number of Products by Stage and Top 10 Target, H1 2014 60
Number of Products by Top 10 Mechanism of Action, H1 2014 62
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 63
Number of Products by Top 10 Route of Administration, H1 2014 65
Number of Products by Stage and Top 10 Route of Administration, H1 2014 66
Number of Products by Top 10 Molecule Type, H1 2014 67
Number of Products by Stage and Top 10 Molecule Type, H1 2014 68

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *